Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Neurosense Therapeutics Ltd WT (NRSNW)

Neurosense Therapeutics Ltd WT (NRSNW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements PR Newswire - Fri Apr 3, 9:02AM CDT

CAMBRIDGE, Mass. , April 3, 2026 /PRNewswire/ --  NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a late-stage clinical biotechnology company developing treatments...

NRSNW : 0.2000 (unch)
NRSN : 0.8300 (+9.21%)
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference PR Newswire - Wed Mar 18, 7:00AM CDT

Dr. Christian Lunetta to Present "From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial"

NRSNW : 0.2000 (unch)
NRSN : 0.8300 (+9.21%)
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity PR Newswire - Mon Mar 16, 10:33AM CDT

The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b trial in ALS, including slower functional...

NRSNW : 0.2000 (unch)
NRSN : 0.8300 (+9.21%)
PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference PR Newswire - Mon Mar 9, 10:07AM CDT

CAMBRIDGE, Mass. , March 9, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...

NRSNW : 0.2000 (unch)
NRSN : 0.8300 (+9.21%)
NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS PR Newswire - Wed Feb 18, 8:05AM CST

CAMBRIDGE, Mass. , Feb. 18, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...

NRSNW : 0.2000 (unch)
NRSN : 0.8300 (+9.21%)
NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease PR Newswire - Wed Jan 21, 7:30AM CST

CAMBRIDGE, Mass. , Jan. 21, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...

NRSNW : 0.2000 (unch)
NRSN : 0.8300 (+9.21%)
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB PR Newswire - Thu Jan 8, 7:45AM CST

Alzheimer's Clinical and Biomarker Outcomes Expected in Q1 2026

NRSNW : 0.2000 (unch)
NRSN : 0.8300 (+9.21%)
NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 PR Newswire - Thu Dec 4, 2025

CAMBRIDGE, Mass. , Dec. 4, 2025 /PRNewswire/ --  NeuroSense Therapeutics Ltd.  (NASDAQ: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe...

NRSNW : 0.2000 (unch)
NRSN : 0.8300 (+9.21%)
NeuroSense to Host Investor Webinar on December 8, 2025 PR Newswire - Mon Nov 3, 2025

Business, regulatory and clinical updates will be provided

NRSNW : 0.2000 (unch)
NRSN : 0.8300 (+9.21%)

Barchart Exclusives

The Market Isn’t Pricing War. It’s Pricing What Comes After Barchart - Sun Apr 5, 2:14PM CDT
Markets aren’t reacting to war; they’re repricing what the war forces to break. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.